From the Molecular Physiology and Genetics Section
and the ¶ Gene Expression and Aging Section, Gerontology Research
Center, NIA, National Institutes of Health,
Baltimore, Maryland 21224
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dopamine (DA) is a neurotransmitter, but it also
exerts a neurotoxic effect under certain pathological conditions,
including age-related neurodegeneration such as Parkinson's disease.
By using both the 293 cell line and primary neonatal rat postmitotic striatal neuron cultures, we show here that DA induces apoptosis in a
time- and concentration-dependent manner. Concomitant with the apoptosis, DA activates the JNK pathway, including increases in JNK
activity, phosphorylation of c-Jun, and subsequent increase in c-Jun
protein. This DA-induced JNK activation precedes apoptosis and is
persistently sustained during the process of apoptosis. Transient
expression of a dominant negative mutant SEK1(Lys Arg), an upstream
kinase of JNK, prevents both DA-induced JNK activation and apoptosis. A
dominant negative c-Jun mutant FLAG
169 also reduces DA-induced
apoptotic cell death. Anti-oxidants N-acetylcysteine and
catalase, which serve as scavengers of reactive oxygen species generated by metabolic DA oxidation, effectively block DA-induced JNK
activation and subsequent apoptosis. Thus, our data suggest that DA
triggers an apoptotic death program through an oxidative stress-involved JNK activation signaling pathway. Given the fact that
the anti-oxidative defense system declines during aging, this molecular
event may be implicated in the age-related striatal neuronal cell loss
and age-related dopaminergic neurodegenerative disorders, such as
Parkinson's and Huntington's diseases.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dopamine (DA)1 is a neurotransmitter under physiological conditions. However, accumulating evidence indicates that DA may also serve as a neurotoxin and thereby participates in the neurodegenerative process. This includes ischemia (1), local exposure to high concentrations of excitatory amino acids (2), and treatment with methamphetamine (3, 4). The DA availability in animal striatum is significantly increased in the above cases. In the case of hypoxia, the striatal DA levels are increased by up to 1100% of control levels (5). Direct injection of high concentration of DA (0.025-0.5 M) into the striatal area results in neurodegeneration (6). DA, 6-OH-DA, and other monoamines are also neurotoxic when directly applied to cell cultures (7-9).
The mechanism of DA neurotoxicity is highly linked to oxidative metabolism. With respect to its molecular structure, DA contains an unstable catechol moiety. DA can oxidize spontaneously in vitro or through an enzyme-catalyzed reaction in vivo to form reactive oxygen species (ROS), free radicals, and quinones (10-12). In the human substantia nigra, the DA oxidation products may further polymerize to form another neurotoxin, neuromelanin (13). These oxidation products can damage cellular components such as lipids, proteins, and DNA (14). Although the cause of age-related degeneration of dopaminergic neurons in Parkinson's disease (PD) is unknown, the oxidative stress induced by DA is believed a major pathological factor. In the "free radical hypothesis," the neurodegeneration in PD is considered to result from high exposure of these dopaminergic neurons to ROS, especially generated by oxidation of DA (15, 16). This hypothesis is supported by postmortem studies showing that in the substantia nigra of PD brain, there are increased indices of oxidative stress, increased levels of iron, increased lipid peroxidation, decreased mitochondrial complex I activity, and decreased levels of glutathione (GSH) (17, 18). Indeed, in vitro studies show that DA (0.01-1 mM) and its metabolic product, 6-OH-DA, can induce apoptosis associated with ROS in a variety of cell types. These include both neuronal and non-neuronal cells, for example primary neonatal rat striatal cell cultures (19, 20), primary chick sympathetic neurons (8), a cloned catecholaminergic cell line (CATH.a) derived from the central nervous system (21), human neuroblastoma NMB cells (22), neuronal PC12 cells (23), and even mouse thymocytes (24). Application of anti-oxidants, such as N-acetylcysteine, catalase, ascorbic acid, and dithiothreitol (DTT) can effectively prevent DA-induced apoptotic cell death (8, 19, 21, 24). However, the molecular events involved in the processes of DA-induced apoptosis are unknown.
Recent evidence suggests that the JNK (also called SAPK) pathway may
play an important role in triggering apoptosis in response to free
radicals generated by ultraviolet and gamma radiation, or direct
application of H2O2, or inflammatory cytokines
(tumor necrosis factor , interleukin-1) (25-29). In response to the
above cellular stresses, JNK is strongly activated (26, 27).
Overexpression of dominant negative mutants of components in the JNK
pathway, such as ASK1(K709R), SEK1(Lys
Arg) (both are upstream
kinases), and c-Jun
169 (a downstream target), can effectively
prevent the apoptosis (29-32). Furthermore, transfection of the
constitutively activated forms of ASK1, SEK1, or c-Jun results in
apoptotic cell death (29-32). Given the role of the JNK pathway in
initiating apoptosis, we test here the hypothesis that DA-induced
apoptosis may also be mediated by JNK activation. We have used both 293 cells and primary neonatal rat striatal cell cultures to test this
hypothesis. Our results indicate that DA indeed triggers cellular
apoptosis through an oxidation-linked JNK activation pathway.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials--
Antibodies against JNK-1 and GST were from Santa
Cruz Biotechnology. Monoclonal anti-c-Jun was from Oncogene. Antibodies
against phospho-specific c-Jun (Ser-63) II and phospho-specific
SAPK/JNK were from New England Biolabs. Anti-Flag M2 monoclonal
antibody was from Kodak. Dopamine was from Research Biochemicals. A
dominant negative SEK1(Lys Arg) vector was provided by Dr. L. Zon
and J. Kyriakis; pCDFLAG
169 DNA was from Dr. L. Rubin and J. Ham.
Cell Cultures and Treatments-- The 293 cells were maintained in IMEM supplemented with 10% fetal bovine serum with 100 units/ml penicillin and 100 µg/ml streptomycin. For primary neonatal striatal cell cultures, the procedures were described previously (33). The striata of neonatal rats (Wistar rat colony of Gerontology Research Center, NIA, National Institutes of Health) were dissected and pooled in Hank's balanced salt solution at 4 °C. Cells were enzymatically dispersed by a mixture of 0.15% collagenase and 0.001% DNase. The cells were then plated on polyethyleneimine-coated chamber slides and cultured in a medium (50% Dulbecco's modified Eagle's medium, 50% Ham's F-12) supplemented with 5% fetal bovine serum and 5% horse serum at 37 °C with 5% CO2. After 3 days, 5 µM cytosine arabinofuranoside was included to inhibit growth of glial cells and fibroblasts. Cell culture medium was routinely changed every 3 to 4 days. Cells were used after 20 days in culture to perform experiments.
To determine changes in JNK activity, phosphorylation of c-Jun and c-Jun protein levels in 293 cells, we incubated the cells with DA in 1% serum-containing medium to reduce background. Apoptosis was determined under the same conditions. In striatal cell cultures, the cells were treated with DA in the complete medium.DNA Analysis and Detection of Apoptotic Cells--
The procedure
for extraction of DNA was followed as described (23). 1 × 106 293 cells were used to isolate DNA for each sample.
Cells were harvested by gentle scraping and collected by centrifugation
for 5 min at 4 °C. The pellet was resuspended with TE buffer (5 mM Tris-HCl, pH 8.0; 20 mM EDTA) containing
0.5% v/v Triton X-100 for 20 min at 4 °C. To remove high molecular
weight DNA, the samples were centrifuged at 14,000 rpm for 30 min in
the presence of 0.1% SDS. The samples were then sequentially extracted
with equal volumes of a mixture of phenol:chloroform:isoamyl alcohol
(25:24:1) and chloroform. The DNA was precipitated with 0.1 volume of 5 M NaCl and 2 volumes of ethanol at 70 °C overnight.
The DNA was resuspended with TE buffer, and the RNA was digested by 0.1 mg/ml RNase for 3 h at 30 °C. The samples were run on 1.4%
agarose gels containing 0.1 µg/ml ethidium bromide, and DNA was
visualized under UV light.
Transient Expressions-- Lipofectin® reagent was used to transfect cDNA plasmids by following the protocol provided by manufacturer (Life Technologies, Inc.). After transfection, the cells were fed with complete medium for 1 additional day. These cells were then used for experiments.
Lysate Preparation--
For determination of JNK activity and
anti-JNK1 immunoblotting, cell extracts were prepared as follows.
Stimulated cells were scraped into tubes and collected by
centrifugation at 4000 rpm for 5 min at 4 °C. The cell pellets were
washed with cold PBS and solubilized with ice-cold JNK lysis buffer
consisting of 25 mM Hepes, pH 7.5, 300 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 20 mM -glycerophosphate, 0.1 mM sodium orthovanadate, 0.5 mM DTT, 100 µg/ml phenylmethylsulfonyl fluoride, and 2 µg/ml leupeptin. The
cellular extract was then centrifuged for 30 min at 14,000 rpm to
remove debris. The supernatant was used immediately or aliquoted and
stored at
70 °C for further use. For anti-phospho-specific c-Jun
and c-Jun immunoblotting, we have used different procedures. Stimulated
cells were collected as described above. The cell pellets were washed
with cold PBS, solubilized with hot SDS lysis buffer (80-90 °C)
consisting of 10 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 0.5 mM EDTA, 1 mM EGTA, 1% SDS, 1 mM sodium orthovanadate, and a mixture of protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml
pepstatin A, 2 µg/ml aprotinin) and heated for 10 min at 90 °C.
The lysates were then sonicated for 10 s and centrifuged for 20 min in a microcentrifuge. The supernatants were used to perform
SDS-PAGE or stored at
70 °C.
Measurement of JNK Activity--
The procedures described by
Coso et al. (34) were used with a slight modification.
Clarified cell lysates (200 µg of proteins) were first incubated
overnight at 4 °C with 10 µg of polyclonal anti-JNK1 and then
incubated with 20 µl of Sepharose A-conjugated protein A for an
additional 1 h. The beads were pelleted and washed three times
with cold PBS containing 1% Nonidet P-40 and 2 mM sodium
orthovanadate, once with cold 100 mM Tris-HCl (pH 7.5) buffer containing 0.5 M LiCl, and once with cold kinase
reaction buffer consisting of 12.5 mM MOPS (pH 7.5), 12.5 mM -glycerophosphate, 7.5 mM
MgCl2, 0.5 mM EGTA, 0.5 mM NaF, and
0.5 mM sodium orthovanadate. The kinase reaction was
performed in the presence of 1 µCi of [
-32P]ATP, 20 µM ATP, 3.3 µM DTT, and 3 µg of substrate
GST-c-Jun-(1-98) in kinase reaction buffer for 30 min at 30 °C and
stopped by addition of 10 µl of 5 × Laemmli loading buffer. The
samples were heated for 5 min at 95 °C and analyzed by 12%
SDS-PAGE. Phosphorylated substrate c-Jun was visualized by
autoradiography. The optical density of autoradiograms was determined
using the NIH Image program. The kinase activity was expressed as fold
of control.
Western Immunoblotting and Immunocytochemistry-- Equal amounts of lysate protein (40 µg/lane) were run on either 10 or 8-16% SDS-PAGE and electrophoretically transferred to nitrocellulose. Nitrocellulose blots were first blocked with 10% nonfat dry milk in TBST buffer (20 mM Tris-HCl (pH 7.4), 500 mM NaCl, and 0.01% Tween 20) and then incubated with primary antibodies (JNK-1, 1:1000, Santa Cruz Biotechnology; Ser(P)-73-specific c-Jun and phospho-SAPK/JNK, 1:1000, New England Biolabs; monoclonal c-Jun, 1:1000, Oncogen; monoclonal anti-Flag M2, 1:1000, Kodak) in TBST containing 5% bovine serum albumin overnight at 4 °C. Immunoreactivity was detected by sequential incubation of horseradish peroxidase-conjugated secondary antibody (1:5000, Jackson ImmunoResearch) and Renaissance substrate (DuPont). For immunocytochemical studies, cells were first washed twice with cold PBS and then fixed with 4% paraformaldehyde in PBS. Immunostaining was performed according to the procedures provided by the manufacturer for the ABC Elite kit. Nonspecific binding was blocked with 5% normal goat or horse serum for 1 h in TBST buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Triton X-100) for 1 h. The cells were then incubated with primary antibody (polyclonal anti-D2 receptor, 1:1000, Chemicon; monoclonal anti-Flag M2, 1:1000, Kodak) overnight at 4 °C in a TBST solution. They were sequentially incubated for 1 h with biotinylated secondary antibody, ABC reagents for 1 h, and then exposed for 5 min to a mixture of hydrogen peroxide, and chromogen, 3,3-diaminobenzidine tetrachloride. The positive staining cells were examined under a light microscope.
Protein Determination-- Two methods were used depending on the detergents used in the preparation of cell lysates. The protein concentration in cellular extracts containing Triton X-100 was determined by Bio-Rad protein reagent (Bio-Rad), and protein in the lysates containing SDS was measured by MicroBCA kit (Pierce product).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dopamine Induces Apoptosis in Non-neuronal and Neuronal Cell Cultures-- We have chosen human embryo kidney 293 cells and neonatal striatal cell cultures as non-neuronal and neuronal cells, respectively, to study the apoptotic effect of dopamine. One of the biochemical features of apoptosis is the early onset of specific endonuclease cleavage of cellular DNA into a nucleosome ladder (35). Considering the limited amount of material available from neonatal rat striatal cell cultures, we first used 293 cells to find optimal conditions for DA-induced apoptosis by examining DNA fragmentation (DNA ladder). 293 cells were plated on 60-mm dishes and grown to about 80% confluency. The cells were then exposed to DA in IMEM containing 1% serum. As expected, DA induced a typical apoptotic DNA ladder with a 200-base pair range increase (Fig. 1, A and B). DA induced DNA fragments in a time- and concentration-dependent manner (Fig. 1, A and B). Exposure of 293 cells to 500 µM DA resulted in DNA cleavage beginning at 16 h and reaching a maximum at 30 h (Fig. 1A). Within 30 h of exposure, DA induced DNA fragmentation at concentrations from 100 µM to at least 500 µM (Fig. 1B). We have repeated these experiments at least 3 times and observed similar time- and concentration-dependent patterns. DA-induced nuclear changes were evaluated under a fluorescence microscope using DAPI staining. In control cells, the nuclei showed uniform staining, indicating that cells were healthy and nuclei were intact. With 500 µM DA treatment for 30 h, some nuclei exhibited typical apoptotic characteristics, such as nuclear condensation and fragmentation (not shown). Apoptotic cells represented 70 ± 5.3% (n = 4) of those cells. Some floating dead cells were also observed at this time point. Based on these observations, we chose maximal stimulation with 500 µM DA for 30 h to observe the DA apoptotic effect in neonatal rat striatal cell cultures.
|
DA Activates the JNK Pathway--
Activation of the JNK pathway
has been implicated in initiating apoptosis in several cases. These
include deprivation of NGF from sympathetic neurons and
NGF-differentiated PC12 cells (30, 32) and exposure of the cells to
lethal dosages of and UV-c irradiation (25, 38). To test the
hypothesis that DA-induced apoptosis may involve the JNK pathway, we
examined the effects of DA on this pathway, which include JNK
activation, phosphorylation of c-Jun, and the amount of c-Jun in both
293 cells and neonatal rat striatal cell cultures.
|
|
JNK/SAPK Signaling Mediates DA-induced Apoptosis--
As mentioned
earlier, the JNK/SAPK pathway involves an orderly activation of
proteins, MEKK1, SEK1, JNK, and c-Jun (26, 27, 31). SEK1 is an upstream
kinase of JNK, and c-Jun is a downstream substrate of activated JNK. We
assessed roles of the JNK pathway in DA-induced apoptosis using a
dominant negative SEK1(Lys Arg) mutant and a c-Jun negative mutant
Flag
169.
|
|
|
|
Anti-oxidants Protect against DA-induced Apoptosis by Inhibition of JNK Activation-- Although DA-induced apoptosis may involve multiple mechanisms, recent evidence suggests that oxidative stress may play an essential role (8, 19, 21, 24). Due to the inherent instability of the catechol moiety of DA, the molecule readily oxidizes to form reactive oxygen species, free radicals, and quinones through autoxidation or enzyme-catalyzed reactions (10-12). These free radicals may initiate apoptosis, since anti-oxidants, such as catalase and N-acetylcysteine (NAC), can block DA-induced apoptosis in different types of cells (8, 19, 21, 24). Given that the DA-induced apoptotic cell death is mediated by the JNK pathway, we examined the effects of anti-oxidants on DA-induced JNK activation and subsequent apoptosis.
Anti-oxidants NAC and catalase inhibited both DA-induced JNK activity and apoptosis. 293 cells were plated on 60-mm dishes and cultured to 80% confluency. The cells were first treated with NAC (1 mM) or catalase (10,000 units/ml) or left untreated (control) for 30 min. These cells were then exposed to 500 µM DA for either 3 or 30 h for determining JNK activity and apoptotic cell death, respectively. As indicated in Fig. 6A, DA alone significantly increased JNK activity and resulted in apoptotic DNA fragmentation. Preincubation of NAC and catalase completely blocked JNK activation and cell death (Fig. 6A). NAC and catalase alone did not have any effect on JNK activity and cell morphological changes. By using a similar protocol, we also tested these compounds on DA-induced apoptotic cell death in neonatal rat striatal cells after 20 days in culture. Similar results were obtained to those for 293 cells (see Fig. 6, B and C). Thus, anti-oxidants protect against DA-induced cell death through inhibition of JNK activation, providing another piece of evidence for an essential role of JNK activation in DA-induced apoptosis.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this paper, we present evidence that DA induces apoptosis in both the 293 cell line and postmitotic striatal neuronal cell cultures. The characteristic apoptotic changes are similar to those observed in other cell types, including cell shrinkage, loss of contact with neighboring cells, nuclear condensation, and fragmentation. We also provided evidence suggesting that the DA-induced apoptosis is mediated by DA oxidation linked to the JNK activation pathway. First, exposure of the cells to DA activates the JNK pathway, including phosphorylation and activation of JNK enzyme, phosphorylation of c-Jun, and increase of c-Jun protein. Second, the DA stimulation of the JNK pathway precedes apoptotic processes. The JNK activation increases after 3-4 h of treatment with DA, whereas apoptotic cells appear after 16 h exposure of the cells to DA. The DA-induced JNK activation pathway tightly correlates with the subsequent apoptosis in a concentration-dependent manner. Third, and most importantly, a dominant negative SEK1 mutant can block DA-induced JNK activation and subsequent phosphorylation of c-Jun as well as apoptosis. Consistent with this result, a negative c-Jun mutant, which presumably blocks c-Jun activation, also inhibits apoptotic cell death by DA. Finally, anti-oxidants, such as NAC and catalase, which both serve as scavengers of free radicals generated by oxidation of DA, completely prevent activation of the JNK and consequent apoptosis. Thus, our data suggest a model by which DA produces ROS, then activates the JNK pathway, resulting in triggering of apoptosis.
Our results indicate that DA induces a persistent activation of the JNK
enzyme, which may play a critical role in initiating the apoptotic
suicide program. DA strongly stimulates JNK activity after 3 to 4 h exposure of cells and maintains it before and during apoptosis for at
least 27 h (Fig. 3A). This longer and sustained JNK
activation may serve as a death signal in DA-induced apoptosis. In
agreement with this view, a similar longer stimulation of the JNK
enzyme was also observed in some environmental stress-induced forms of
apoptosis. For example, exposure of Jurkat cells to lethal doses of and UV-c radiation rapidly increases JNK activity after 30 min and can
last at least 12 h without significant effect on p38 MAP kinase
and ERK activity (25, 38). Withdrawal of NGF from differentiated PC12
neuronal cells results in persistent activation of JNK and p38 MAP
kinase with inhibition of ERK activity (30). Although there are
variable effects on p38 MAP kinase and ERK activities in the different
cell systems described above, the JNK activation is persistent and
shows a direct correlation with the apoptosis. Furthermore, repression
of JNK activation by transfection of a dominant negative mutant JNK1
prevents
and UV-c irradiation-induced apoptosis (25, 38).
Overexpression of a dominant negative mutant of upstream kinase MEKK1
for JNK inhibits apoptosis induced by deprivation of NGF from
differentiated PC12 cells (30). In our case, transfection of a dominant
negative mutant of SEK, an upstream kinase for JNK, also blocks
DA-induced apoptosis (Fig. 4A and Table I). All of these
observations indicate that a longer and sustained JNK activation is
essential to induce apoptosis in some types of cell death. The
DA-induced persistent JNK activation may be produced by the continued
stimulation of upstream enzymes of JNK due to cellular damage by ROS of
DA oxidation (see below). The alternative pathway for prolonged JNK
activation may be inactivation of dual specificity phosphatase, an
enzyme that can dephosphorylate JNK and ERK resulting in
down-regulation of the activities (43).
DA treatment also results in sustained activation of c-Jun protein. c-Jun is a transcriptor and can positively autoregulate its own expression by JNK which can directly bind to and phosphorylate the c-Jun transactivation domain on serines 63 and 73 (27, 44). DA increases both the amount of c-Jun and the phosphorylation of c-Jun with a similar time course. This observation suggests that the phosphorylated c-Jun could be entirely due to the increase in c-Jun protein. The increased c-Jun protein could be phosphorylated since JNK enzyme was still highly activated during this time (Fig. 3A). Our data are also similar to the observation by Ham et al. (32) that NGF withdrawal results in an increase in c-Jun protein accompanied by slower migration of phosphorylated c-Jun. This positive feedback regulatory mechanism for c-Jun activation may play a crucial role in triggering apoptosis induced by DA.
It should also be noted that the time course of JNK activation differs from that of c-Jun phosphorylation. One possible explanation might be a difference in the time required for active JNK to translocate from the cytosol to the nucleus. Another possibility might be the existence of a c-Jun phosphatase whose activation is affected by dopamine.
How does activation of the JNK pathway by DA induce apoptosis? One
possibility is that activation of JNK pathway may stimulate the genes
that promote cell proliferation. Like the hypothesis of apoptosis of
sympathetic neurons induced by withdrawal of neurotrophic factors, cell
death is assumed to result from an inappropriate attempt to reenter the
cell cycle in such terminally differentiated neurons (32, 45, 46).
According to this model, deprivation of neurotrophic factor would
trigger expression of genes related to cyclin-dependent
kinases that promote entry into the cell cycle. By using a reverse
transcription-polymerase chain reaction technique, Freeman et
al. (47) reported that cyclin D1 mRNA is selectively increased
at 15-20 h after NGF withdrawal. During this time, the sympathetic
neuron is subject to dying. Ham et al. (32) suggested that
cyclin D1 expression is probably driven by c-Jun-involved AP-1 activity
since the cyclin D1 promoter has a potential AP-1 binding site and
c-Jun is activated 4-8 h after NGF deprivation. Consistent with this
model, there was a report that DA can alter cell cycle and force human
neuroblastoma NMB cells to accumulate in S/M2 phase (22).
This alteration of the cell cycle by DA accompanies apoptosis, peaking
at 16-24 h, and is concentration-dependent. Cycloheximide, a
protein synthesis inhibitor, blocks both changes in the cell cycle and
apoptosis induced by DA (22). In agreement with this view, our results
show that the JNK pathway is stimulated after DA application for 3 h. It might be expected that c-Jun activation through the DA-induced
JNK pathway stimulates AP-1 activity-involved cell cycle gene
transcription that promotes cell proliferation. NAC, in addition to its
anti-oxidation effect, also inhibits cell proliferation in PC12 cells
(48). The ability of NAC to inhibit DNA synthesis is parallel to its
function to promote survival of PC12 cells and sympathetic neurons
following deprivation of serum or NGF (48). Our data show that NAC also inhibits both DA-induced JNK activation and apoptosis. It is possible that DA stimulates the JNK pathway and then activates cell cycle gene
expression through c-Jun-dependent AP-1 activity, driving cells into an inappropriate cell cycle, such as accumulation in the
S/G2 phase, finally resulting in apoptosis. NAC, a
scavenger of free radicals generated by DA, inhibits JNK activity and
potential subsequent abortive attempts to re-enter the cell cycle, thus preventing cell death. Although the current data favor this model, other possibilities still exist. For example, DA-induced JNK activity may regulate interleukin-1 converting enzyme family members.
The oxidative products of DA may serve as stimuli to activate the JNK
pathway and subsequent apoptosis. As mentioned in the Introduction, DA
can be metabolized to form ROS, such as H2O2, O2, and OH· through either
autoxidation or enzyme-catalyzed reactions (10-12). Like other
environmental stresses, such as ionizing irradiation, UV radiation, and
heat shock, the ROS can activate both JNK and apoptosis in a variety of
cell systems (29). In agreement with this idea, our data show that
anti-oxidants including NAC, a scavenger of ROS, and catalase, an
enzyme that hydrolyzes H2O2 into
H2O and O2, prevent DA-induced JNK activation
and subsequent apoptosis. Other anti-oxidants, such as ascorbic acid
and DTT, also have protective effects against DA toxicity (8, 20).
Bcl-2 is an oncogene product and is intracellularly located in the
places where ROS is generated, such as mitochondria, endoplasmic
reticulum, and nuclear membranes (49). Bcl-2 inhibits ROS-induced
apoptosis through regulation of an anti-oxidation pathway (49). Using an antisense probe on Bcl-2 to reduce its expression increases the
sensitivity of the CATH.a cell line to the toxic effects of DA (21).
Moreover, overexpression of Bcl-2 in PC12 cells can block JNK activity
induced by deprivation of serum (50). In vivo, since the
enzymes catalyzing DA metabolism occur intracellularly, blockage of the
DA transporter by either application of its selective inhibitors, such
as bupropion, or down-regulation using antisense oligonucleotides
effectively reduces DA cytotoxicity in bovine chromaffin cells and
human neuroblastoma NMB cells, respectively (22, 51). Blockage of DA
entry into these cells is assumed to reduce the generation of ROS. We
are currently investigating the potential mechanisms of ROS production
by DA activation of the JNK pathway and apoptosis.
The molecular events of DA oxidation-JNK pathway may be implicated in senescent DA receptor containing neuron loss in striatum. One of the most obvious manifestations of brain aging is a selective loss of D2-dopamine receptors from the corpus striatum (52). This decrement has been observed in rodents, as well as primates including humans (52, 53). During aging, D2-dopamine (DA) receptor-containing neurons in striatum are decreased about 25-30% (52, 54). Although the cause of the neuron death is not well understood, recent evidence suggest that apoptosis may be involved in this process. In old rats, the frequency of apoptotic striatal cells is significantly increased compared with young animals (55). In aged rodent brains, decreased levels of GSH and mitochondrial cytochromes as well as mitochondrial dysfunction have been reported (56, 57). Anti-oxidant activities are also reported to be decreased during aging (58). These senescent changes would accumulate ROS products of DA, resulting in activation of an apoptotic suicide program.
It is known that apoptosis is a normal process during development. In certain brain regions, cell death can occur in 50% of the neurons produced by neurogenesis (59). From this view, apoptosis is considered an active process to protect the organism from mutation and overgrowing (60). During development of dopaminergic neurons, DA has been shown to be required for neurogenesis (61). As cell proliferation and apoptosis often share similar biochemical pathways, increased levels or enhanced overflow of DA due to hypoxia or exposure to excitatory amino acids may trigger apoptosis of postmitotic neurons in the brain, based on our in vitro data. However, in the case of Parkinson's disease, the anti-oxidative system including catalase, glutathione peroxidase, as well as levels of glutathione are decreased in substantia nigra neurons, suggesting greater susceptibility to the oxidative stress produced by DA (15, 16). Recent in vitro data show that the levels of GSH are important to maintain the granular storage of DA in rat PC12 cells (62) and function of DA transport in the rat striatal synaptosomes (63). The normal catecholamine concentration in dopaminergic cell bodies is estimated to be approximately 0.1-1 mM (64). Based on the above information, one may hypothesize why the selective increase of DA oxidation exists in the age-related PD brain. Indeed, in substantia nigra, the increased oxidation of DA is observed by an increased ratio of free cysteinyl DA relative to DA (65, 66). There is evidence suggesting that the neurons containing greater amounts of neuromelanin, a polymerization product of oxidized DA, are most susceptible to neuronal death in PD (67, 68). The possibility of DA oxidation-induced apoptosis in PD brain has not been evaluated. However, apoptotic cell death has been identified in the hippocampus from postmortem Alzheimer's brain, and apoptotic cells are co-localized with c-Jun proteins, suggesting a potential mechanism for neurodegenerative disease (69, 70).
Like other in vitro studies, DA produces apoptosis in a concentration range between 0.1 and 0.5 mM. This concentration is much higher than that needed for physiological function in the synapse (low micromolar levels) (71). However, we believe that our observations are of potential relevance to pathological situations for the following reasons. 1) We exposed the cells to DA during a relatively short 30-h period and observed apoptosis and its associated biochemical signaling, while the neurodegeneration process in vivo may develop over decades. 2) We carried out experiments with healthy young cells possessing a strong anti-oxidative stress system. In the aged individual developing Parkinsonism, there occurs a deteriorating metabolic system with reduced defense ability against ROS produced by DA oxidation. We are currently investigating these problems in rats with different age groups.
In summary, we have presented data to show that DA can induce apoptosis
in both dividing cells and neonatal striatal neuronal cell cultures.
The DA-induced apoptosis occurs in a time- and concentration-dependent manner. Corresponding to its
apoptotic action, DA activates the JNK pathway indicated by stimulation of JNK, phosphorylation of c-Jun, and increase of c-Jun and occurs before activation of a cell "suicide" program. A negative mutant SEK1(Lys Arg) blocks DA-induced JNK activation and subsequent apoptosis. The c-Jun negative mutant also prevents DA-induced apoptosis. Anti-oxidants including both NAC and catalase can block both
DA-induced JNK activation and apoptosis, indicating that DA-induced
oxidative stress is involved. Since the anti-oxidation defense system
declines during aging, DA-induced apoptosis with involvement of the JNK
pathway may play a role in neuron loss from the striatum during aging
and Parkinson's and Huntington's diseases, age-related dopaminergic
neurodegenerative disease. The demonstration of the oxidation-JNK
pathway in DA-induced apoptosis may offer potential means to protect
against the damage of aging and age-related diseases, such as
increasing defenses against free radicals and blocking the JNK
activation pathway.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. Y. Liu and Y. Wang for helpful
discussions; Dr. N. J. Holbrook for critical reading of the
manuscript and constructive suggestions; Dr. L. Zon and J. Kyriakis for
SEK1(Lys Arg) vector; Dr. L. Rubin and J. Ham for pCDFLAG
169
DNA.
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Molecular Physiology and Genetics Section, Gerontology Research Center, NIA, National Institutes of Health, 4E02, 4940 Eastern Ave., Baltimore, MD 21224. Tel.: 410-558-8507; Fax: 410-558-8323; E-mail: luoyq{at}helix.nih.gov.
1 The abbreviations used are: DA, dopamine; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; JNK, c-Jun NH2-terminal kinase (also called SAPK); MAPK, mitogen-activated protein kinase; MOPS, 4-morpholinepropanesulfonic acid; NGF, nerve growth factor; PAGE, polyacrylamide gel electrophoresis; SEK1, SAPK/Erk kinase 1; DTT, dithiothreitol; PBS, phosphate-buffered saline; IMEM, improved minimum essential medium (Eagle's with 4 mM glutamine; ROS, reactive oxygen species; PD, Parkinson's disease; DAPI, 4,6-diamidino-2-phenylindole; NAC, N-acetylcysteine.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|